Table III.
Metabolite | Mean AFC (95% CI)1 | Difference in mean AFC | % Change (95% CI) | P-value2 |
---|---|---|---|---|
∑DEHP (µmol/l) | ||||
Q1 (0.02–0.09) | 14.2 (13.2, 15.2) | 0 (ref) | – | – |
Q2 (0.10–0.21) | 10.7 (9.9, 11.6) | −3.5 | −24% (−32, −16) | <0.001 |
Q3 (0.21–0.44) | 11.5 (10.7, 12.5) | −2.7 | −19% (−27, −9) | 0.002 |
Q4 (0.46–18.88) | 12.1 (11.2, 13.1) | −2.1 | −14% (−23, −5) | 0.004 |
P-trend3 | 0.34 | |||
MEHP (µg/l) | ||||
Q1 (0.21–1.62) | 14.1 (13.1, 15.2) | 0 (ref) | – | – |
Q2 (1.63–3.50) | 12.0 (11.1, 13.0) | −2.1 | −15% (−23, −5) | 0.003 |
Q3 (3.53–6.53) | 10.2 (9.3, 11.0) | −3.9 | −28% (−36, −20) | <0.001 |
Q4 (6.71–265) | 12.3 (11.4, 13.2) | −1.8 | −13% (−22, −3) | 0.009 |
P-trend | 0.33 | |||
MEHHP (µg/l) | ||||
Q1 (1.00–7.50) | 13.4 (12.5, 14.5) | 0 (ref) | – | – |
Q2 (8.21–17.70) | 11.7 (10.8, 12.6) | −1.7 | −13% (−22, −3) | 0.01 |
Q3 (17.90–40.57) | 10.9 (10.1, 11.9) | −2.5 | −19% (−27, −9) | 0.0002 |
Q4 (41.10–1977) | 12.5 (11.6, 13.5) | −0.9 | −7% (−16, 4) | 0.20 |
P-trend | 0.92 | |||
MEOHP (µg/l) | ||||
Q1 (0.94–5.10) | 13.9 (12.9, 15.0) | 0 (ref) | – | – |
Q2 (5.14–11.12) | 11.5 (10.7, 12.5) | −2.4 | −17% (−26, −7) | 0.0009 |
Q3 (11.22–24.90) | 11.4 (10.5, 12.3) | −2.5 | −18% (−27, −9) | 0.0003 |
Q4 (25.03–1278) | 11.7 (10.9, 12.7) | −2.2 | −16% (−24, −6) | 0.002 |
P-trend | 0.06 | |||
MECPP (µg/l) | ||||
Q1 (3.17–13.40) | 14.0 (13.0, 15.1) | 0 (ref) | – | – |
Q2 (13.50–29.34) | 10.9 (10.1, 11.8) | −3.1 | −22% (−30, −13) | <0.001 |
Q3 (29.63–58.45) | 12.0 (11.1, 12.9) | −2.0 | −14% (−23, −5) | 0.004 |
Q4 (59.10–2109) | 11.7 (10.8, 12.6) | −2.3 | −17% (−25, −7) | 0.001 |
P-trend | 0.08 | |||
MEP(µg/l) | ||||
Q1 (3.43–25.20) | 12.6 (11.7, 13.6) | 0 (ref) | – | – |
Q2 (27.60–54.02) | 12.5 (11.6, 13.5) | −0.1 | −1% (−11, 10) | 0.81 |
Q3 (54.17–138.85) | 11.3 (10.4, 12.2) | −1.3 | −11% (−20, 0) | 0.04 |
Q4 (139.11–5995) | 12.1 (11.2, 13.1) | −0.5 | −4% (−14, 7) | 0.47 |
P-trend | 0.68 | |||
MBP (µg/l) | ||||
Q1 (0.60–7.35) | 13.1 (12.2, 14.2) | 0 (ref) | – | – |
Q2 (7.43–12.75) | 11.9 (11.0, 12.8) | −1.2 | −10% (−19, 1) | 0.07 |
Q3 (12.79–22.14) | 11.0 (10.1, 12.0) | −2.1 | −16% (−25, −6) | 0.002 |
Q4 (22.50–140.20) | 12.5 (11.6, 13.5) | −0.6 | −5% (−15, 6) | 0.34 |
P-trend | 0.57 | |||
MCPP (µg/l) | ||||
Q1 (0.30–1.70) | 12.0 (11.1, 13.0) | 0 (ref) | – | – |
Q2 (1.71–2.65) | 11.7 (10.8, 12.7) | −0.3 | −2% (−13, 9) | 0.67 |
Q3 (2.66–5.50) | 12.0 (11.1, 13.0) | 0 | 0% (−10, 12) | 0.94 |
Q4 (5.56–61.70) | 12.8 (11.9, 13.8) | 0.8 | 7% (−4, 19) | 0.23 |
P-trend | 0.11 | |||
MiBP (µg/l) | ||||
Q1 (0.50–3.50) | 12.7 (11.8, 13.7) | 0 (ref) | -- | - |
Q2 (3.61–6.75) | 12.8 (11.9, 13.8) | 0.1 | 1% (−10, 12) | 0.92 |
Q3 (6.75–10.21) | 11.1 (10.3, 12.1) | −1.6 | −13% (−22, −2) | 0.02 |
Q4 (10.28–90.0) | 11.9 (11.0, 12.9) | −0.8 | −6% (−16, 4) | 0.23 |
P-trend | 0.12 | |||
MBzP (µg/l) | ||||
Q1 (0.22–1.63) | 12.1 (11.1, 13.0) | 0 (ref) | – | – |
Q2 (1.71–3.24) | 12.0 (11.1, 13.0) | −0.1 | 0% (−11, 11) | 0.93 |
Q3 (3.30–6.28) | 12.6 (11.7, 13.6) | 0.5 | 4% (−6, 17) | 0.44 |
Q4 (6.39–75.19) | 11.9 (11.0, 12.9) | −0.2 | −1% (−12, 10) | 0.81 |
P-trend | 0.80 | |||
MCOP (µg/l) | ||||
Q1 (0.92–5.56) | 12.3 (11.4, 13.4) | 0 (ref) | – | – |
Q2 (5.80–14.19) | 11.7 (10.8, 12.7) | −0.6 | −5% (−16, 6) | 0.36 |
Q3 (14.23–42.80) | 12.3 (11.4, 13.3) | 0 | 0% (−11, 12) | 0.96 |
Q4 (43.22–520.0) | 12.8 (11.8, 13.9) | 0.5 | 4% (−7, 16) | 0.52 |
P-trend | 0.23 | |||
MCNP (µg/l) | ||||
Q1 (0.51–2.06) | 12.0 (11.0, 13.0) | 0 (ref) | – | – |
Q2 (2.07–3.53) | 11.6 (10.7, 12.7) | −0.4 | −3% (−14, 9) | 0.62 |
Q3 (3.53–6.50) | 13.0 (12.0, 14.0) | 1.0 | 8% (−3, 22) | 0.16 |
Q4 (6.75–160.5) | 12.6 (11.6, 13.6) | 0.6 | 5% (−6, 18) | 0.41 |
P-trend | 0.35 |
1Poisson regression models adjusted for maternal age (continuous), BMI (continuous) and smoking status (never, ever).
2P-value is for test of significant difference between the quartile of interest and quartile 1.
3Tests for linear trend were performed using the median level of urinary phthalate metabolite in each quartile in the regression model, adjusting for covariates.